Signal transduction underlying carbachol-induced contraction of rat urinary bladder.

II. Protein kinases*

Marina Fleichman, Tim Schneider, Charlotte Fetscher, Martin C. Michel

Dept. of Medicine (MF, TS, CF, MCM) and Urology (TS), University of Essen, Essen,

Germany and Dept. of Pharmacology and Pharmacotherapy, University of Amsterdam,

Amsterdam, Netherlands (MCM)

1

Running title: Protein kinases in muscarinic bladder contraction

Corresponding author:

Prof. Martin C. Michel

Academisch Medisch Centrum

Afd. Farmacologie en Farmacotherapie

Meibergdreef 15

1105 AZ Amsterdam, Netherlands

Phone: +31-20-566-6762

Fax: +31-20-696-5976

E-mail: m.c.michel@amc.uva.nl

Number of text pages: 14 (including references)

Number of tables: 0

Number of figures: 6

Number of references: 28

Words in Abstract: 212

Words in Introduction: 271

Words in Discussion: 902

Non-standard abbreviations:

DMSO; dimethylsulfoxide

ERK; extracellular signal-regulated kinase

MAPK, mitogen-activated protein kinases

2

PI-3-kinase, phosphatidylinositol-3-kinase

PKC, protein kinase C

Recommended section assignment: other

ABSTRACT

We have investigated the role of several protein kinases in carbachol-stimulated, M_3

muscarinic receptor-mediated contraction of rat urinary bladder. Concentration-response

curves for the muscarinic receptor agonist carbachol were generated in the presence of multiple

concentrations of inhibitors of various protein kinases, their inactive controls or their vehicles.

Bladder contraction was not significantly inhibited by three protein kinase C inhibitors

(chelerythrine 1-10 μM, calphostin C 0.1-1 μM and Gö 6850 1-10 μM), by the tyrosine kinase

inhibitor genistein or its inactive control daidzein (3-30 μM each) or by two inhibitors of

activation of mitogen-activated protein kinase (PD 98,059 10-100 μM and U 126 3-30 μM) or

their negative control U 124 (3-30 μM). While high concentrations of wortmannin (3-30 μM)

inhibited bladder contraction, this was not mimicked by another inhibitor of

phosphatidylinositol-3-kinase, LY 294,002 (3-30 μM) and hence more likely due to direct

inhibition of myosin light chain kinase by wortmannin than to an involvement of

phosphatidylinositol-3-kinase. In contrast, Y 27,632 (1-10 μM), an inhibitor of rho-associated

kinases, concentration-dependently and effectively attenuated the carbachol responses. We

conclude that carbachol-induced contraction of rat urinary bladder does not involve protein

kinase C, phosphatidylinositol-3-kinase, tyrosine kinases or extracellular signal-regulated

kinases; in contrast rho-associated kinases appear to play an important role in the regulation of

bladder contraction.

4

Muscarinic acetylcholine receptors are the physiologically most important mechanism to mediate contraction of the urinary bladder (Andersson, 1993). Although rat bladder expresses more M_2 than M_3 receptors, contractile responses to the exogenous muscarinic agonist carbachol and to endogenous agonist released by field stimulation occur predominantly if not exclusively via M_3 receptors in rats (Longhurst et al., 1995;Hegde et al., 1997;Choppin et al., 1998;Tong et al., 1997;Braverman et al., 1998;Longhurst and Levendusky, 2000;Kories et al., 2003). In the accompanying paper we have confirmed the involvement of M_3 but not M_2 receptors in carbachol-induced contraction and have demonstrated that this involves nifedipine-sensitive Ca^{2+} channels and, to a smaller degree, phosphoplipases D and A_2 and store-operated Ca^{2+} channels, but not cyclooxygenase and surprisingly also not phospholipase C (Schneider et al., 2003). Overall, this pattern of proximal signaling mediating urinary bladder smooth muscle contraction shares many properties with that of other types of smooth muscle such as vascular smooth muscle. Such proximal signaling pathways are connected to smooth muscle contraction by a network of protein kinases. Kinases which have been implied mediating the contraction of vascular smooth muscle include protein kinase C (PKC) (Aburto et al., 1995;Dessy et al., 1998), phosphatidylinositol-3-kinase (PI-3-kinase) (Ibitayo et al., 1998), tyrosine kinases (Jinsi et al., 1996;Di Salvo et al., 1997) including those of the src family (Roberts, 2001), mitogen-activated protein kinases (MAPK) particularly those of the extracellular signal-regulated kinase (ERK) family (Dessy et al., 1998;Fetscher et al., 2001), and rho-associated kinase (Mukai et al., 2001;Fukata et al., 2001;Altmann et al., 2003). Therefore, we have investigated possible roles of these kinases in the carbachol-induced M_3 receptor-mediated contraction of rat bladder.

METHODS

Force of contraction: Urinary bladder strips were prepared from female Wistar rats (265 ± 4 g

bladder weight, 77 ± 1 mg bladder weight, n = 40) obtained from the central animal breeding

facility at the University of Essen. Experiments were performed as previously described

(Kories et al., 2003). Briefly, longitudinal bladder strips (approximately 1 mm diameter, 17 ±

1 mm length, 10.1 ± 0.3 mg weight, n = 143) were mounted under a tension of 10 mN in 10 ml

organ baths containing Krebs-Henseleit solution (119 mM NaCl, 25 mM $NaHCO_3$, 4.7 mM

KCl, 1.18 mM KH_2PO_4, 1.17 mM $MgSO_4$, 2.5 mM $CaCl_2$, 0.027 mM EDTA, 5.5 mM glucose

and 10 mM HEPES) which was aerated with 95% O_2 and 5% CO_2 to yield a pH of 7.4 at 37°C.

After 60 min of equilibration including washes with fresh buffer every 15 min, the bladder

strips were challenged three times with a combination of 50 mM KCl and 0.1 mM carbachol

with 5 min rest and washes between each challenge. Following washout and an additional 30

min of equilibration, cumulative concentration-response curves were constructed for carbachol

in the absence of any inhibitor or vehicle. Using washout and 15 min equilibration periods in

between, up to 3 additional curves were then generated in the presence of increasing

concentrations of the indicated inhibitors, their negative controls or their vehicles.

Carbachol concentration-response curves were analyzed by fitting sigmoidal curves to the

experimental data, in which the bottom of the curve was fixed at 0. The force of contraction in

the absence and presence of inhibitors were expressed as % of maximum carbachol effects

observed within the same bladder strip in the first concentration-response curve, i.e. prior to

addition of any inhibitor or vehicle. To assess inhibitor effects, alterations in E_{max} or pEC_{50} in

its presence relative to the first curve were compared to those in the presence of a matching

6

vehicle time control using two-way analysis of variance testing for main treatment effect and concentration-dependency; if this indicated statistical significance, the effect of individual inhibitor concentrations relative to time-matched controls was assessed by Bonferroni post-tests. A $p < 0.05$ was considered to be significant in all statistical analyses. All curve fitting and statistical calculations were performed with the Prism program (version 4.0, Graphpad Software, San Diego, CA).

Chemicals Carbachol HCl, PD 98,059 (2'-amino-3'-methoxyflavone) and wortmannin were obtained from Sigma-Aldrich (Taufkirchen, Germany). Calphostin C (from *Cladosporium cladosprioides*), chelerythrine HCl, LY 294,002 (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one), LY 303,511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one), U 124 (1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene) and U 126 (1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene) were obtained from Calbiochem (Bad Soden, Germany). Y 27,632 (trans-4-[(1R)-1-aminoethyl]-N-4-pyridinylcyclohexanecarboxamide) was from Tocris (Bristol, UK).

Calphostin C (at 1 mM), chelerythrine (at 1 mM), daidzein (at 10 mM), genistein (at 10 mM) Gö 6850 (at 1 mM), LY 294,002 (at 10 mM), LY 303,511 (at 10 mM), PD 98,059 (at 100 mM), U 124 (at 10 mM), U 126 (at 10 mM) and wortmannin (at 1 mM) were dissolved in dimethylsulfoxide (DMSO). Y 27,632 (at 10 mM) was dissolved in water.

7

RESULTS

Prior to addition of any inhibitor, carbachol concentration-dependently increased force of
contraction with a pEC_{50} of 5.75 ± 0.02 and maximum effects of 38.1 ± 1.0 mN (n = 143 strips).
All further data are expressed as % of the maximum carbachol effect in the same preparation
prior to addition of any inhibitor, negative control or vehicle.

A potential role of PKC was assessed using the inhibitors chelerythrine (1-10 µM, figure 1),
calphostin C (0.1-1 µM, supplementary figure 1
http://jpet.aspetjournals.org/cgi/content/full/jpet.103.058255/DC1) and Gö 6850 (1-10 µM, supplementary
figure 2 http://jpet.aspetjournals.org/cgi/content/full/jpet.103.058255/DC2), with the latter being a selective
inhibitor of classical PKC isoforms. None of the three inhibitors significantly affected the
potency or maximum effects of carbachol-induced bladder contraction relative to paired
time-control experiments in the presence of vehicle.

To test a possible role of PI-3-kinase in carbachol-induced bladder contraction, the inhibitors
wortmannin (3-30 µM, figure 2) and LY 294,002 (3-30 µM, figure 3) as well as LY 303,511
(3-30 µM, supplementary figure 3 http://jpet.aspetjournals.org/cgi/content/full/jpet.103.058255/DC3), a
negative control for LY 294,002 were tested. Wortmannin caused statistically significant
inhibition of carbachol-induced contraction at concentrations starting at a concentration of 3
µM and almost completely abolished the carbachol effects at 30 µM; the inhibition by
wortmannin involved reduction of both, the potency and maximal effects of carbachol (figure
2). In contrast, LY 294,002 did not cause statistically significant inhibition of
carbachol-induced bladder contraction (figure 3). LY 303,511, despite not being an inhibitor

8

of PI-3-kinase, caused statistically significant reductions of carbachol potency (but not

maximal responses) at all concentrations which had been tested (supplementary figure 3

http://jpet.aspetjournals.org/cgi/content/full/jpet.103.058255/DC3).

A potential role of tyrosine kinases was tested using the inhibitor genistein (3-30 µM, n = 6,

figure 4) and its negative control daidzein (3-30 µM, n = 6, supplementary figure 4

http://jpet.aspetjournals.org/cgi/content/full/jpet.103.058255/DC4). Neither genistein nor daidzein

significantly affected the potency or maximal effects of carbachol-induced bladder

contraction.

To test a possible role MAPK of the ERK type, we have used the MAPK kinase inhibitors PD

98,059 (10-100 µM, n = 6, figure 5) and U 126 (3-30 µM, n = 6, supplementary figure 5

http://jpet.aspetjournals.org/cgi/content/full/jpet.103.058255/DC5) and U 124 (3-30 µM, n = 7, supplementary

figure 6 http://jpet.aspetjournals.org/cgi/content/full/jpet.103.058255/DC6), a negative control for the latter.

None of the three inhibitors significantly affected the potency or maximal effects of carbachol

in rat urinary bladder.

To test a role of rho-associated kinase, its inhibitor Y 27,632 (1-10 µM, n = 6, figure 6) was

tested. Y 27,632 concentration-dependently inhibited carbachol-induced bladder contraction,

and this inhibition consisted mainly of a reduction of maximum responses (by 13 $\forall$ 1%, 22 $\forall$

3% and 61 $\forall$ 4%) with only moderate reduction in pEC_{50} (by 0.028 $\forall$ 0.05, 0.45 $\forall$ 0.05 and

0.57 $\forall$ 0.06 log units) with 1, 3 and 10 µM Y 27,632, respectively.

9

DISCUSSION

The muscarinic acetylcholine receptor agonist carbachol mediates contraction of rat bladder

via M_3 receptors (Longhurst et al., 1995;Hegde et al., 1997;Choppin et al., 1998;Tong et al.,

1997;Braverman et al., 1998;Longhurst et al., 2000;Kories et al., 2003). The accompanying

manuscript has described the relative roles of proximal signalling pathways in mediating this

response (Schneider et al., 2003). In other types of smooth muscle these proximal pathways are

linked to smooth muscle contraction by a network of protein kinases, but the specific wiring

depends on the receptor and type of smooth muscle under investigation. The present study has

investigated the possible involvement of a number of protein kinases in carbachol-induced M_3

receptor-mediated contraction of rat urinary bladder which have previously been implied in

mediating the contraction of vascular smooth muscle (see introduction). Recent studies have

highlighted the problem that a number of prototypical kinase inhibitors can also have effects

unrelated to inhibition of their cognate kinase (Davies et al., 2000;El-Kholy et al.,

2003;Altmann et al., 2003). Therefore, the present study, whenever possible, has used multiple,

chemically unrelated kinase inhibitors as well as negative controls, i.e. chemically related

compounds which lack kinase inhibition, in order to minimize problems related to non-specific

inhibitor effects.

A role for PKC in mediating agonist-stimulated contraction of vascular smooth muscle has

been identified in some vessels for some receptors (Aburto et al., 1995;Dessy et al., 1998)

whereas the same or other receptors in different vessels elicited vasoconstriction without

intermediate PKC activation (Fetscher et al., 2001;Shirao et al., 2002). In the present study,

three chemically distinct PKC inhibitors failed to significantly affect carbachol-induced

10

contraction of rat urinary bladder despite being tested in high concentrations. Since PKC

activation, particularly of the classical PKC isoforms which are sensitive to inhibition by Gö

6850, frequently occurs secondary to phospholipase C activation, and since experiments

shown in the accompanying paper did not detect a role for phospholipase C in urinary bladder

contraction (Schneider et al., 2003), these data demonstrate that the phospholipase C/PKC

cascade may be activated by muscarinic receptors in rat bladder (Livak and Schmittgen,

2001;Schneider et al., 2003) but is not crucial for induction of contraction.

Activation of a PI-3-kinase has also been implicated in contraction of colonic (Ibitayo et al.,

1998) but not vascular smooth muscle (Altmann et al., 2003). In the present study, a high

concentration of one inhibitor (wortmannin) inhibited carbachol-induced bladder contraction,

whereas another one (LY 294,002) did not. In this context, it should be noted that high

concentrations of wortmannin (but not of LY 294,002) were also shown to inhibit skeletal

muscle contraction in a manner independent from PI-3-kinase inhibition (Hong and Chang,

1998), possibly by directly inhibiting myosin light chain kinase (Takayama et al., 1996). The

unexpected inhibitory effect of LY 303,511, a negative control for LY 294,002 with regard to

PI-3-kinase inhibition, was not further investigated in the present study but may relate to other

actions of this compound such as inhibition of certain K^+ channels (El-Kholy et al., 2003) or

direct blockade of certain receptors (Altmann et al., 2003). The overall data, however, indicate

that PI-3-kinase is not involved in mediating carbachol-induced contraction of rat urinary

bladder.

Tyrosine kinases (Jinsi et al., 1996;Di Salvo et al., 1997;Janssen et al., 2001) including those

of the src family (Roberts, 2001) can also mediate smooth muscle contraction in some

preparations but not in others (Fetscher et al., 2001;Altmann et al., 2003). In the present study

neither the tyrosine kinase inhibitor genistein nor its negative control daidzein inhibited

bladder contraction, indicating that tyrosine kinases do not play a major role in this regard.

Recently it was demonstrated that inhibitors of MAPK activation, particularly of MAPK of the

ERK family, can also inhibit smooth muscle contraction in some cases (Dessy et al.,

1998;Fetscher et al., 2001;Roberts, 2001) but not in others (Watts et al., 1998;Janssen et al.,

2001;Altmann et al., 2003). In the present study neither PD 98,059 nor U 126 nor its negative

control U 124 significantly inhibited carbachol-induced contraction of rat urinary bladder.

Hence, ERK activation does not appear to be required to contract this type of smooth muscle.

Rho-associated kinase is gaining attention as a universal regulator of smooth muscle tone. It is

expressed at high levels in rat urinary bladder, and its inhibitor Y 27,632 attenuates bladder

contraction induced by stimulation of muscarinic, purinergic or neurokinin A receptors

(Wibberley et al., 2003). A similar inhibition was also seen in the present study. Studies in

other tissues indicate that this can involve several different mechanisms including a direct

effect on myosin light chains, effects on CPI-17, a phosphorylation-dependent inhibitory

protein of myosin phosphatase, and, perhaps most importantly, a direct inhibition of myosin

phosphatase (Fukata et al., 2001). Which of these mediates the effects on bladder contraction,

remains to be investigated.

Taken together it appears that a range of protein kinases, which has been implicated in

mediating contraction of other types of smooth muscle such as PKC, PI-3-kinase, tyrosine

kinases and MAPK of the ERK family, do not play a major role in mediating

12

carbachol-induced M_3 muscarinic receptor-mediated contraction of rat urinary bladder. In contrast, this and previous data (Wibberley et al., 2003) suggest that rho-associated kinase is an important mediator of bladder contraction. Further studies at the subcellular level appear necessary to elucidate the molecular pathways linking proximal signal transduction of the muscarinic receptor to the activation of rho-associated kinase and ultimately urinary bladder smooth muscle contraction.

REFERENCES

Aburto T, Jinsi A, Zhu Q, and Deth RC (1995) Involvement of protein kinase C activation in α_2-adrenoceptor-mediated contractions of rabbit saphenous vein. *Eur.J.Pharmacol.* **277**:35-44.

Altmann C, Steenpaß V, Czyborra P, Hein P, and Michel MC (2003) Comparison of signalling mechanisms involved in rat mesenteric microvessel contraction by noradrenaline and sphingosylphosphorylcholine. *Br.J.Pharmacol.* **138**:261-271.

Andersson K-E (1993) Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. *Pharmacol.Rev.* **45**:253-308.

Braverman AS, Luthin GR, and Ruggieri MR (1998) M_2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. *Am.J.Physiol.* **275**:R1654-R1660.

Choppin A, Eglen RM, and Hegde SS (1998) Pharmacological characterization of muscarinic receptors in rabbit isolated iris sphincter muscle and urinary bladder smooth muscle. *Br.J.Pharmacol.* **124**:883-888.

Davies SP, Reddy H, Caivano M, and Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. *Biochem.J.* **351**:95-105.

Dessy C, Kim I, Sougnez CL, Laporte R, and Morgan KG (1998) A role for MAP kinase in differentiated smooth muscle contraction evoked by α-adrenoceptor stimulation. *Am.J.Physiol.* **275**:C1081-C1086.

Di Salvo J, Nelson SR, and Kaplan N (1997) Protein tyrosine phosphorylation in smooth

14

muscle: a potential coupling mechanism between receptor activation and intracellular calcium. *Proc.Soc.Exp.Biol.Med.* **214**:285-301.

El-Kholy, W., MacDonald, P. E., Lin, J.-H., Wang, J., Fox, J. M., Light, P. E., Wang, Q., Tsushima, R. G., and Wheeler, M. B. The phosphatidylinositol 3-kinase inhibitor LY294002 potently blocks K_V currents via a direct mechanism. FASEB Journal 17(6), 720-722. 2003. Ref Type: Internet Communication

Fetscher C, Chen H, Schäfers RF, Wambach G, Heusch G, and Michel MC (2001) Modulation of noradrenaline-induced microvascular constriction by protein kinase inhibitors. *Naunyn-Schmiedeberg's Arch.Pharmacol.* **363**:57-65.

Fukata Y, Amano M, and Kaibuchi K (2001) Rho-rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. *Trends Pharmacol.Sci.* **22**:32-39.

Hegde SS, Choppin A, Bonhaus D, Briaud S, Loeb M, Moy TM, Loury D, and Eglen RM (1997) Functional role of M_2 and M_3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. *Br.J.Pharmacol.* **120**:1409-1417.

Hong SJ and Chang CC (1998) Novel inhibition of contractility by wortmannin in skeletal muscle. *Br.J.Pharmacol.* **124**:849-856.

Ibitayo AI, Tsunoda Y, Nozu F, Owyang C, and Bitar KN (1998) Src kinase and PI 3-kinase as a transduction pathway in ceramide-induced contraction of colonic smooth muscle. *Am.J.Physiol.* **275**:G705-G711.

Janssen LJ, Premji M, Netherton S, Coruzzi J, Lu-Chao H, and Cox PG (2001) Vasoconstrictor

actions of isoprostanes via tyrosine kinase and Rho kinase in human and canine pulmonary vascular smooth muscles. *Br.J.Pharmacol.* **132**:127-134.

Jinsi A, Paradise J, and Deth RC (1996) A tyrosine kinase regulates α-adrenoceptor-stimulated contraction and phospholipase D activation in the rat aorta. *Eur.J.Pharmacol.* **302**:183-190.

Kories C, Czyborra C, Fetscher C, Schneider T, Krege S, and Michel MC (2003) Gender comparison of muscarinic receptor expression and function in rat and human urinary bladder: differential regulation of $M_{2 \text{ and } M3?}$ *Naunyn-Schmiedeberg's Arch.Pharmacol.* **367**:524-531.

Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT Method. *Methods* **25**:402-408.

Longhurst PA, Leggett RE, and Briscoe JAK (1995) Characterization of the functional muscarinic receptors in the rat urinary bladder. *Br.J.Pharmacol.* **116**:2279-2285.

Longhurst PA and Levendusky M (2000) Influence of gender and the oestrous cycle on in vitro contractile responses of the rat urinary bladder to cholinergic stimulation. *Br.J.Pharmacol.* **131**:177-184.

Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J, Kaibuchi K, and Takeshita A (2001) Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. *FASEB J.* **10.1096/fj.00-0735fje**.

Roberts RE (2001) Role of the extracelluar signal-regulated kinase (Erk) signal transduction cascade in α_2 adrenoceptor-mediated vasoconstriction in porcine palmar lateral vein. *Br.J.Pharmacol.* **133**:859-866.

Schneider T, Hein P, and Michel MC (2003) Signal transduction underlying carbachol-induced

16

contraction of rat urinary bladder. I. Phospholipases and Ca^{2+} sources. *J.Pharmacol.Exp.Ther.* **this volume**.

Shirao S, Kashiwagi S, Sato M, Miwa S, Nakao F, Kurokawa T, Todoroki-Ikeda N, Mogami K, Mizukami Y, Kuriyama S, Haze K, Suzuki M, and Kobayashi S (2002) Sphingosylphosphorylcholine is a novel messenger for rho-kinase-mediated Ca^{2+} sensitization in the bovine cerebral artery. Unimportant role for protein kinase C. *Circ.Res.* **91**:112-119.

Takayama M, Ozaki H, and Karaki H (1996) Effects of a myosin light chain kinase inhibitor, wortmannin, on cytoplasmic Ca^{2+} levels, myosin light chain phosphorylation and force in vascular smooth muscle. *Naunyn-Schmiedeberg's Arch.Pharmacol.* **354**:120-127.

Tong Y-C, Hung Y-C, Lin S-N, and Cheng J-T (1997) Pharmacological characterization of the muscarinic receptor subtypes responsible for the contractile response in the rat urinary bladder. *J.Auton.Pharmacol.* **17**:21-25.

Watts SW, Florian JA, and Monroe KM (1998) Dissociation of angiotensin II-stimulated activation of mitogen-activated protein kinase kinase from vascular contraction. *J.Pharmacol.Exp.Ther.* **286**:1431-1438.

Wibberley A, Chen Z, Hu E, Hieble JP, and Westfall TD (2003) Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle. *Br.J.Pharmacol.* **138**:757-766.

Footnote page

Address for reprint requests:

Prof. Martin C. Michel

Academisch Medisch Centrum

Afd. Farmacologie en Farmacotherapie

Meibergdreef 15

1105 AZ Amsterdam, Netherlands

Phone: +31-20-566-6762

Fax: +31-20-696-5976

E-mail: m.c.michel@amc.uva.nl

LEGENDS TO THE FIGURES

Figure 1: Effects of the protein kinase C inhibitor chelerythrine and its vehicle DMSO (final concentration $\leq$ 1%) on carbachol-induced contraction (n = 6).

Figure 2: Effects of the phosphatidylinositol-3-kinase inhibitor wortmannin and its vehicle DMSO (final concentration $\leq$ 3%) on carbachol-induced contraction (n = 8). ** and ***: $p < 0.01$ and < 0.001, respectively, vs. matching time controls in the presence of vehicle in a two-way analysis of variance followed by Bonferroni post-tests.

Figure 3: Effects of the phosphatidylinositol-3-kinase inhibitor LY 294,002 and its vehicle DMSO (final concentration $\leq$ 0.3%) on carbachol-induced contraction (n = 8).

Figure 4: Effects of the tyrosine kinase inhibitor genistein and its vehicle DMSO (final concentration $\leq$ 0.3%) on carbachol-induced contraction (n = 6).

Figure 5: Effects of PD 98,059, an inhibitor of the activation of mitogen-activated protein kinases, and its vehicle DMSO (final concentration $\leq$ 0.1%) on carbachol-induced contraction (n = 6).

Figure 6: Effects of the rho kinase inhibitor Y 27,632 and its vehicle water (final concentration $\leq$ 0.1%) on carbachol-induced contraction (n = 6). ** and ***: $p < 0.01$ and < 0.001, respectively, vs. matching time controls in the presence of vehicle in a two-way analysis of variance followed by Bonferroni post-tests.

19

Supplementary figure 2: Effects of the protein kinase C inhibitor Gö 6850 and its vehicle DMSO (final concentration ≤ 1%) on carbachol-induced contraction (n = 7).

Supplementary figure 3: Effects of LY 303,511, a negative control for the phosphatidylinositol-3-kinase inhibitor LY 294,002, and its vehicle DMSO (final concentration $\leq$ 0.3%) on carbachol-induced contraction (n = 8). ***: p < 0.001 vs. matching time controls in the presence of vehicle in a two-way analysis of variance followed by Bonferroni post-tests.

Effects of U 124, a negative control for U 126, and its vehicle DMSO (final concentration $\leq$ 0.3%) on carbachol-induced contraction (n = 7).